Fasiglifam 25 mg BID vs 50 mg QD
Public ClinicalTrials.gov record NCT01982253. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Placebo-Controlled, Double-Blind Parallel-Group, Multicenter Study to Evaluate the Glycemic Effects and Safety of Fasiglifam 25 mg Twice Daily and 50 mg Once Daily on Glycemic Control in Subjects With Type 2 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the efficacy of fasiglifam 25 mg twice daily (BID) and fasiglifam 50 mg once daily (QD) on glycemic control in adults with type 2 diabetes who are inadequately controlled on diet and exercise alone.
Study identification
- NCT ID
- NCT01982253
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2013
- Primary completion
- Dec 31, 2013
- Completion
- Dec 31, 2013
- Last update posted
- Oct 6, 2016
2013 – 2014
United States locations
- U.S. sites
- 47
- U.S. states
- 21
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Goodyear | Arizona | — | — |
| Not listed | Long Beach | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | North Hollywood | California | — | — |
| Not listed | Norwalk | California | — | — |
| Not listed | Tustin | California | — | — |
| Not listed | Boynton Beach | Florida | — | — |
| Not listed | Coral Gables | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Pembroke Pines | Florida | — | — |
| Not listed | Decatur | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Avon | Indiana | — | — |
| Not listed | Franklin | Indiana | — | — |
| Not listed | Greenfield | Indiana | — | — |
| Not listed | Muncie | Indiana | — | — |
| Not listed | Council Bluffs | Iowa | — | — |
| Not listed | Topeka | Kansas | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Metairie | Louisiana | — | — |
| Not listed | Flint | Michigan | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Greensboro | North Carolina | — | — |
| Not listed | Mooresville | North Carolina | — | — |
| Not listed | Morganton | North Carolina | — | — |
| Not listed | Salisbury | North Carolina | — | — |
| Not listed | Maumee | Ohio | — | — |
| Not listed | Norman | Oklahoma | — | — |
| Not listed | Corvallis | Oregon | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Harleysville | Pennsylvania | — | — |
| Not listed | Levittown | Pennsylvania | — | — |
| Not listed | Uniontown | Pennsylvania | — | — |
| Not listed | Greer | South Carolina | — | — |
| Not listed | Carrollton | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Edinburg | Texas | — | — |
| Not listed | Houstan | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | New Braunfels | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Spring | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Burke | Virginia | — | — |
| Not listed | Manassas | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
Recently updated Type 2 Diabetes Mellitus trials
Other public records listing Type 2 Diabetes Mellitus. Sorted by last update posted; newest first. Not a recommendation.
- NCT07743450: A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes Recruiting
- NCT07662044: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus Recruiting
- NCT07521475: Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes Recruiting
- NCT07662135: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin Recruiting
- NCT07662109: A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus Recruiting
- NCT07662213: A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01982253, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2016 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01982253 live on ClinicalTrials.gov.